SOURCE: Carling Communications

Carling Communications

April 19, 2011 09:00 ET

Carling Communications, Inc. Hired as Agency of Record by ThromboGenics, Inc.

SAN DIEGO, CA--(Marketwire - Apr 19, 2011) - San Diego based healthcare communications agency, Carling Communications, Inc. has been chosen by ThromboGenics, Inc. as its agency of record for its brand development, promotional planning, and medical education efforts. Carling will work with ThromboGenics, a biopharmaceutical company headquartered in Leuven, Belgium and offices in Ireland and New York to implement the brand plan for its first major commercial launch.

Carling, a full-service marketing agency, was hired by ThromboGenics to assist in commercial readiness in anticipation for the global launch of ocriplasmin (microplasmin), a pharmacologic agent being developed for the treatment of symptomatic vitreomacular adhesion, a vision-threatening disease that affects the retina. Within medical education, Carling will manage all aspects of communication with key opinion leaders in the industry and shape awareness of both disease and product within the ophthalmology arena. In addition, Carling will collaborate with ThromboGenics in the development of various campaigns to raise both physician and patient awareness of this disease, and will drive the creative development of the product's brand identity.

"This is a tremendous win for Carling Communications. ThromboGenics chose Carling based on our strategic marketing skills, and our ability to thoughtfully execute initiatives across a span of services, from promotional advertising and branding to medical education," commented Didi Discar, Principal at Carling Communications. "Developing a brand that is going to address this unmet need for physicians all over the world, and patients across several different countries, is an extraordinary opportunity for our agency, and particularly exciting for our growing team."

"Carling Communications has the experience, skills and strategic capabilities necessary to bring our product to launch and help accelerate our company's already rapid growth," said Ram Palanki, Head of U.S. Marketing at ThromboGenics. "Carling provides a great opportunity for the success and development of our brand portfolio, in addition to adding a new level of involvement with the ophthalmic medical community that will drive continued success in an exhilarating and focused direction."

About Carling Communications, Inc.
Carling Communications, Inc., located in San Diego, California, is a global provider of branding and medical education programs. The company shares its philosophy, focused on a purposeful existence and the commitment to forging partnerships that contain chemistry and success. Carling Communications offers an extensive suite of state-of-the-art services in conjunction with innovative brand development.

About ThromboGenics, Inc.
ThromboGenics is a biopharmaceutical company focused on the discovery and development of innovative medicines for the treatment of eye disease, vascular disease, and cancer. The Company's lead product ocriplasmin (microplasmin) has completed two successful phase III clinical trials for the pharmacological treatment of symptomatic vitreomacular adhesion (sVMA). ThromboGenics will commercialize this product via its own dedicated sales force in the United States and in Europe.

In addition, ThromboGenics is developing novel antibody therapeutics in collaboration with BioInvent International; these include TB-402 (anti-Factor VIII), a long-acting anticoagulant in phase II, and TB-403 (anti-PlGF) in phase Ib/II for cancer in partnership with Roche.

ThromboGenics has currently around 75 employees at its headquarters in Leuven, Belgium, and at its facilities in Ireland and the United States. The Company is listed on Eurolist by Euronext Brussels under the symbol THR.

Contact Information

  • Media Contact:
    Jamie Hall
    Account Executive
    Pascale Communications, LLC
    o: 412.531.1551
    c: 724.417.0167
    e: Email Contact